FindMyKOL
Clinical trialNCT06252675RecruitingPhase 2Interventional

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

SponsorUniversity of California, San FranciscoEnrollment30Mantle Cell Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of California, Davis

    Davis, California, United States

    Naseem Shams Esteghamat, MD
    Recruiting
  • University of California, Los Angeles

    Los Angeles, California, United States

    Patricia Young, MD
    Recruiting
  • University of California, San Diego

    San Diego, California, United States

    Erin Reid, MD
    Recruiting
  • University of California, San Francisco

    San Francisco, California, United States

    C. Babis Andreadis, MDMadhav Seshadri, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Glofitamab →Obinutuzumab →Pirtobrutinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Jun 2024
Primary completion
31 Jul 2028
Completion
31 Jul 2028
Last update posted
1 Oct 2026
Registered enrollment
30
Registry id
NCT06252675
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.